GP · sexual-health-and-gender-diversity
STI screening and management
Also known as Sexually transmitted infections · STI testing · Sexual health screening
GP-fellowship guide to STI screening and management: which NAAT sites to test in whom (urine, throat, rectal — extragenital testing matters in MSM), syphilis serology interpretation including prozone, doxycycline-first chlamydia therapy, ceftriaxone-based gonorrhoea treatment amid resistance, test-of-cure versus retesting intervals, partner notification with expedited partner therapy, outpatient PID, PrEP counselling, and pregnancy adjustments.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- Testicular pain with a high-riding tender testis in a young man — torsion until proven otherwise; do not label epididymo-orchitis without excluding torsion
- Pelvic pain with cervical motion tenderness in a woman — treat as PID on clinical grounds the same day; delay risks tubal infertility and ectopic pregnancy
- Any pregnant woman with syphilis serology discordance or unclear treatment history — obstetric escalation; congenital syphilis is preventable but lethal
- Suspected gonorrhoea with sepsis or disseminated infection (pustules, tenosynovitis, joint pain) — same-day systemic treatment
Overview
Sexually transmitted infection (STI) screening in general practice follows exposure, not assumptions. NAAT on first-catch urine covers urethral and cervical infection but misses pharyngeal and anorectal infection, which are common, usually asymptomatic, and sustain transmission. Among 343 gay and bisexual men screened at all three sites, genital-only testing would have missed 71.4% of chlamydia and 67.3% of gonorrhoea infections; among women reporting extragenital exposure, about a quarter of infections would have been missed.[11]
Syphilis has returned, particularly among MSM; its diagnosis rests on understanding two complementary serologic arms. Gonorrhoea treatment is squeezed by resistance — the reason ceftriaxone dose was raised and why entirely new oral agents (zoliflodacin) are entering practice.[15]
References19ShowHide
- [1]Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021 MMWR Recomm Rep, 2021.PMID 34292926
- [2]Geisler WM, Bachmann LH, Brotman RM, et al. Diagnosis and Management of Uncomplicated Chlamydia trachomatis Infections in Adolescents and Adults: Summary of Evidence Reviewed for the US Preventive Services Task Force Clin Infect Dis, 2022.PMID 35416965
- [3]Kong FYS, Tabrizi SN, Law M, et al. The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis J Antimicrob Chemother, 2015.PMID 25637520
- [4]Read TRH, Fairley CK, Hocking JS, et al. Azithromycin or Doxycycline for Asymptomatic Rectal Chlamydia trachomatis N Engl J Med, 2021.PMID 34161706
- [5]Ferreira A, Young T, Mathews C, et al. Strategies for partner notification for sexually transmitted infections, including HIV Cochrane Database Syst Rev, 2013.PMID 24092529
- [6]Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial Am J Obstet Gynecol, 2002.PMID 12015517
- [7]Janier M, Unemo M, Dupin N, et al. 2020 European guideline on the management of syphilis J Eur Acad Dermatol Venereol, 2021.PMID 33094521
- [8]Luryi KM, Lawrence S, Wilson E, et al. Reverse Sequence Syphilis Screening and Discordant Results in Pregnancy J Pediatr, 2020.PMID 32093931
- [9]Liu LL, Lin LR, Tong ML, et al. The prozone phenomenon in syphilis testing South Med J, 2004.PMID 15108820
- [10]Okwundu CI, Uthman OA, Akor A, et al. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals Cochrane Database Syst Rev, 2012.PMID 22786505
- [11]Chow EPF, Ong JJ, Howarth K, et al. Chlamydia and Gonorrhea Infections in Genital and Extragenital Samples Among Men and Women Sex Transm Dis, 2025.PMID 40772619
- [12]Whiley DM, Goire N, Lahra MM, et al. Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of extragenital gonorrhoea Clin Microbiol Infect, 2020.PMID 31419483
- [13]Golden MR, Kerani RP, Stenger M, et al. Uptake and population-level impact of expedited partner therapy (EPT) on Chlamydia trachomatis and Neisseria gonorrhoeae: the Washington State community-level randomized trial of EPT PLoS Med, 2015.PMID 25590331
- [14]Jacobson GF, Autry AM, Kirby RS, et al. A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy Am J Obstet Gynecol, 2001.PMID 11408852
- [15]Luckey A, Balasegaram M, Barbee LA, et al. Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international randomised controlled non-inferiority trial Lancet, 2026.PMID 41391465
- [16]Wong A, Lima N, Applegate TL, et al. Viability of Chlamydia trachomatis in Different Anatomical Sites: a Systematic Review and Meta-analysis Clin Infect Dis, 2026.PMID 39102890
- [17]Smith KS, Guy R, Danielewski J, et al. Biological and Behavioral Factors Associated With Positive Chlamydia Retests Sex Transm Dis, 2017.PMID 28608791
- [18]Hui BB, Hocking JS, Braat S, et al. Intensified partner notification and repeat testing can improve the effectiveness of screening in reducing Chlamydia trachomatis prevalence Sex Transm Infect, 2022.PMID 34815362
- [19]Sadiq ST, Frimpong L, Lawrence S, et al. Spontaneous clearance of genital and extragenital Neisseria gonorrhoeae: data from GToG Sex Transm Infect, 2020.PMID 32732336